Eli Lilly Partners with AI Biotech Profluent Bio on $2.25B Genetic Medicine Deal
Key Takeaways
- ▸Profluent's AI models will design custom DNA editing enzymes to enable kilobase-scale genetic editing, addressing a critical unmet need in genetic medicine
- ▸Eli Lilly gains exclusive licensing and development rights with up to $2.25B in potential milestone payments plus royalties on net sales
- ▸The partnership reflects the pharma industry's growing reliance on AI to accelerate drug discovery and overcome traditional limitations in genetic therapies
Summary
Eli Lilly and AI biotech Profluent Bio announced a landmark research partnership worth up to $2.25 billion focused on developing next-generation DNA editing tools. Profluent will leverage its AI models to design site-specific recombinases—enzymes that cut and rejoin DNA—for multiple genomic targets, with Lilly gaining exclusive licensing rights to selected assets for preclinical, clinical, and commercial development.
The collaboration targets 'kilobase-scale DNA editing,' a major advancement that would allow researchers to insert larger pieces of DNA than current technology enables. This capability is critical for treating genetic diseases caused by multiple mutations, which currently present significant therapeutic challenges. By using AI to design custom recombinases, the partners aim to create therapies previously considered impossible.
Profluent will receive an undisclosed upfront payment, additional R&D funding from Lilly, and up to $2.25 billion in development and commercial milestone payments, plus royalties on net sales. The deal reflects Lilly's accelerating investment in AI-driven drug discovery, following recent partnerships with NVIDIA and Insilico Medicine, and acquisitions of genetic medicine and oncology platforms.
- Deal complements Lilly's broader AI strategy, including recent collaborations with NVIDIA and Insilico Medicine and acquisitions of genetic editing platforms
